The COVID-19 Cicada Variant in 2026: What You Need to Know Right Now

What Is the COVID-19 Cicada Variant (BA.3.2)?

The COVID-19 Cicada variant, officially designated BA.3.2, is a highly mutated strain of SARS-CoV-2 that has recently grabbed the attention of global health officials. It was first identified in South Africa in November 2024 and first detected in a U.S. traveler in June 2025.

So why “Cicada”? The nickname is a clever nod to the actual cicada insect — those noisy bugs that disappear underground for years and then suddenly emerge in massive numbers. Similarly, BA.3.2 circulated largely undetected for more than a year before scientists began noticing a steady uptick in cases in early 2026.

What makes this variant particularly notable is the sheer number of genetic changes it carries. According to virologist Andrew Pekosz, Ph.D. from the Johns Hopkins Bloomberg School of Public Health, BA.3.2 is “highly genetically divergent,” carrying roughly 70 to 75 mutations in its spike protein — the part of the virus that latches onto human cells.

The World Health Organization (WHO) officially added Cicada to its “variants of monitoring” list on February 23, 2026, which signals that health officials are watching it closely — but it has not yet been elevated to a “variant of concern.”

Where Is the Cicada Variant Spreading Right Now?

The Cicada COVID variant is no longer just a regional concern. As of the latest CDC data, BA.3.2 has been detected in at least 23 countries across multiple continents, and it’s been found in wastewater surveillance samples from 132 monitoring sites across at least 25 U.S. states.

In some parts of Northern Europe — including Germany, Denmark, and the Netherlands — Cicada already accounts for roughly 30% of COVID-19 sequences as of January 2026. That’s a significant footprint for a variant that was barely on anyone’s radar just a few months ago.

In the U.S., BA.3.2 is not yet dominant. The current leading strain is still XFG (also called “Stratus”), which accounts for about 53% of samples, according to Stanford’s WasteWaterSCAN tool. BA.3.2 was detected in only about 3.7% of wastewater samples as of mid-March 2026.

However, Dr. Robert H. Hopkins Jr., medical director of the National Foundation for Infectious Diseases, has raised the possibility that Cicada “could drive a U.S. summer surge” — especially as warmer months bring more travel and indoor gatherings.

Symptoms of the COVID-19 Cicada Variant: What to Watch For

Here’s some reassuring news: the symptoms of the Cicada variant are largely similar to those seen with other recent COVID strains. According to the CDC’s 2026 guidelines, common COVID-19 symptoms to watch for include:

• 🤒 Fever or chills
• 😮‍💨 Cough (dry or with mucus)
• 😴 Fatigue and body aches
• 🤧 Runny nose or congestion
• 🤕 Headache
• 😮 Sore throat — some reports mention a “razorblade throat” sensation
• 🤢 Nausea or vomiting
• 💨 Shortness of breath in more serious cases
• 👅 Loss of taste or smell (less common with newer variants)

One symptom worth highlighting is what’s being informally called a “razorblade throat” — an intense sore throat reported by a growing number of COVID patients. Dr. Hopkins noted, “Severe sore throat is reported as a common symptom along with other typical COVID symptoms.”

Importantly, experts do not believe Cicada causes more severe illness than currently circulating strains. “I have not seen any data which indicates that Cicada is any more severe than other circulating variants,” Dr. Hopkins said.

Do Current COVID Vaccines Still Work Against Cicada?

This is probably the question on everyone’s mind — and the honest answer is: it’s complicated, but not hopeless.

The 2025–2026 COVID-19 vaccines currently available in the U.S. were formulated to target variants from the JN.1 lineage — the dominant strains of late 2024 and early 2025. BA.3.2 (Cicada), however, has diverged significantly from that lineage with its 70+ mutations in the spike protein.

In laboratory studies, current vaccines were found to be less effective against BA.3.2 compared to other circulating strains — but researchers stress that more real-world data is needed before drawing firm conclusions.

Here’s the important part: vaccines still offer meaningful protection against severe disease and death, even if they’re less effective at preventing infection from Cicada. Your immune system isn’t completely in the dark — there’s still some cross-reactivity, meaning your body recognizes enough of the virus to mount a defense.

Health experts are also pointing to the possibility of vaccine reformulation to better target BA.3.2 if it continues to spread. The CDC is actively monitoring the situation and will update guidance accordingly.

How to Protect Yourself From the Cicada Variant

Despite the new headlines, the good news is that protecting yourself from the Cicada variant doesn’t require anything dramatically different from what we’ve all learned over the past few years. The basics still work — and they work well.

Neil Maniar, director of the Master of Public Health program at Northeastern University, put it simply: “The biggest focus is really on protecting higher-risk individuals and continuing standard precautions.”

One encouraging piece of news: experts confirm that COVID antiviral drugs — such as Paxlovid — remain effective against the Cicada variant. “The new variant is still sensitive to COVID antiviral drugs that we have been developing, so at least those will work,” said virologist Adolfo García-Sastre of the Icahn School of Medicine at Mount Sinai.

As we head into warmer months with increased travel and social gatherings, Maniar warns that “outbreaks can happen very quickly.” The best defense is awareness combined with action. Don’t panic — but don’t get complacent either.

As Maniar noted, “At this point, COVID is something that’s part of our day-to-day lives, similar to the flu and other respiratory illnesses.” Treat it accordingly: with awareness, common sense, and appropriate precautions.

Frequently Asked Questions About the COVID-19 Cicada Variant